Compare CDNA & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | SGP |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 932.9M |
| IPO Year | 2007 | N/A |
| Metric | CDNA | SGP |
|---|---|---|
| Price | $22.86 | $19.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $28.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 583.8K | 50.1K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $455.40 | ★ N/A |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $10.96 | $19.46 |
| 52 Week High | $23.24 | $30.56 |
| Indicator | CDNA | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 29.82 |
| Support Level | $15.80 | N/A |
| Resistance Level | $22.89 | $26.29 |
| Average True Range (ATR) | 0.95 | 1.59 |
| MACD | 0.11 | -0.38 |
| Stochastic Oscillator | 90.52 | 2.61 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.